Ionis finds new partner in a young biotech and its hopeful founder
Omri Gottesman came to the US from the UK 10 years ago, wide-eyed like many others.
The human genome project was long-complete and, with great fanfare, researchers were beginning to try and leverage those insights into treatments. Mount Sinai School of Medicine offered him a fellowship focused on just that: genomic medicine.
“At the time, there was a lot of hope and hype that we had solved health, and would be able to discover and prevent everything and treat everyone,” Gottesman told Endpoints News. “It was the reason I came to Mount Sinai.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
